Dearman announced that Park Vale Capital has committed to invest £16 million in the business. This brings the total funds raised by Dearman during 2015 to £19.5 million (excluding grant funding), and will allow the company to bring the first application of its technology to market. It will also enable Dearman to establish initial UK-based manufacturing activity, and to achieve widespread international commercial deployment, while continuing to invest in R&D and demonstration of its core technology and subsequent applications.
As a global investor with an established presence in Europe, the USA and Asia, along with expertise in the bio-medical, cyber technology and real estate sectors, Park Vale will work in partnership with Dearman, helping it to establish new markets for its technology, identify opportunities for growth and realise them.
Discussing the announcement, Katherine Priestley, Managing Director of Park Vale said: “Dearman is an extremely exciting company that is developing unique technology to address a clear global need - clean cold. Although the applications of Dearman technology will bring demonstrable environmental benefits, it is the fact that they are also commercially attractive and even operationally superior that makes the company so promising. We look forward to working closely with the Dearman team to help maximise the impact of their innovation and the value we can create together.”